Participant Experience, Acceptability and Feasibility of Virtual and Digitally Supported Visits in a Phase IIa COPD Trial Authors: Renate Kat, Wytske van der Veen, Yoran H. Gerritsma, Marika T. Leving, William Dott, Olga Elizarova, Rod Hughes, Caroline Jonstrand, Cecilia Kristensson, Andrzej Nowojewski, Alex Wheal, Janwillem W. H. Kocks Published: 2026 ABSTRACT Understanding participant experience is crucial for improving participant satisfaction, retention, data quality, and clinical trial efficiency; particularly when incorporating digital patient solutions and virtual elements. CRESCENDO, an international phase-II chronic obstructive pulmonary disease (COPD) trial, incorporated daily at-home digital measurements, remote coached spirometry, and a virtual visit to evaluate feasibility and participant acceptance.This study explored participant experience in CRESCENDO through semi-structured interviews (n=21) and a Study Participant Feedback Questionnaire (SPFQ, n=81), conducted across Bulgaria, Canada, Poland, Spain, UK, and USA. Interview data were analysed thematically.Participants were generally satisfied and found digital and virtual elements user-friendly, although technical issues caused frustration. When functioning properly, participants considered remote and in-person spirometry coaching comparable. Nonetheless, participants preferred in-person visits due to positive interactions with trial staff, which increased satisfaction and feeling of appreciation. High concordance between interview and SPFQ data supported the validity of qualitative interviews for assessing participant experience.The study highlights the potential of digital elements and offers practical recommendations, like providing options for in-person and virtual visits, to enhance satisfaction and engagement.This qualitative sub-study was conducted within the CRESCENDO trial (https://clinicaltrials.gov reference: NCT05492877). Introduction The complexity of clinical trial designs may hinder participant recruitment, compliance, and retention. 1 In the context of clinical trials, patient experience can be assumed to be the first-hand knowledge a person has on receiving health-care services. 2 Therefore, to increase efficiency and improve participant experience, it is crucial to obtain feedback from participants and identify aspects of the trial design that may require improvement. 3 Although opportunities to enhance patient engagement in clinical trials have increased, more work is needed. 3 Participant feedback becomes especially valuable when incorporating novel procedures, such as digital patient solutions aimed at reducing overall participant burden.3,4 Digital solutions, such as smartphones, clinical devices or wearables, have become increasingly available over the past years. 5 When tested and implemented well, such solutions enable remote trial participation and real-time data-collection on outcomes that matter to participants, increasing medical service accessibility (e.g., by reducing in-person visits). This could reduce trial burden for participants and increase the amount and quality of clinical trial data. 4 The CRESCENDO trial evaluated the safety and efficacy of a novel myeloperoxidase (MPO) inhibitor in patients with COPD, a disease that impacts daily life and can make everyday tasks challenging. For this trial, participants performed home-based measurements twice-daily for 24 weeks. 6 Multiple digital patient solutions were implemented, which were hypothesized to improve participant experience and reduce participant burden. The primary and secondary endpoints were collected using the UNIFY application(Unify (Unified Trial Solution) is a clinical trial solution developed by AstraZeneca with modular features such as eCOA, telehealth, home supply and others. The solution includes a patient mobile application and a platform for healthcare professionals.) on a phone and a hand-held spirometer (connected to the phone via Bluetooth). The trial also incorporated virtual trial elements, namely a virtual trial visit and virtually coached spirometry, both performed through a video-connection (e.g., Zoom). Besides general experiences and satisfaction of participants, CRESCENDO enabled the assessment of the feasibility and acceptability of these innovative digital patient solutions and virtual elements, including virtually coached spirometry, 6 from a participant’s perspective. Remote spirometry shows promise particularly for clinical trials as it correlates well with in-clinic measurements and reduces logistical burden for participants thereby contributing to increased engagement.7-10 However, to meet the requirements of the European Medicines Agency, such as the American Thoracic Society and European Respiratory Society standards for spirometry, 11 remote coaching remains crucial to ensure accuracy and consistency of the collected data. Studies on AI-based quality control tools support the need for coaching to maintain high-quality remote spirometry. 12 It is therefore necessary to inspect whether remote spirometry is equivalent to in-person spirometry assessments. Participant feedback is essential to determine practical feasibility and acceptance of remote spirometry, 13 ensuring that the advancing technology is implemented in ways that optimise trial experience, ultimately enhancing recruitment, compliance and retention. 14 For instance, in the case of remote spirometry, previous studies have shown that its implementation is feasible when offering care to patients with COPD.15-18 However, findings about the trial-related experiences of patients with COPD with remote spirometry are very scarce.18,19 Thus, this study aimed to gather more in-depth information about participants’ experiences, with a specific focus on the feasibility and acceptance of the virtual elements introduced in the trial. Through participant interviews, we aimed to gain insights into how these digital technologies are perceived and to identify any barriers or concerns that might hinder the use of these technologies. Methods Study Design This qualitative sub-study was conducted within the CRESCENDO trial (https://clinicaltrials.gov reference: NCT05492877). CRESCENDO is a Phase-IIa randomised, double-blind, placebo-controlled, parallel arm, multi-centre trial to evaluate the efficacy and safety of AZD4831, a myeloperoxidase inhibitor, in moderate to severe COPD. Throughout this manuscript, we will refer to CRESCENDO as “trial”, and to our study as “study”. The trial consisted of 8 visits (Vs) (Figure 1). V1 and V2 were screening visits. At V3, participants were randomized into the 24-week intervention period during which participants performed the home measurements twice-daily. These measurements consisted of completing an electronic diary (eDiary) in the UNIFY application on a provided phone (iOS) and a peak expiratory flow (PEF) measurement on a handheld spirometer (Spirobank Smart, MIR Medical International Research, Rome, Italy) which was connected to the phone via Bluetooth.Figure 1.Topics in the Trial visit overview for the CRESCENDO trial. Screening occurred during V1-2 by the Health Care Professional (HCP). randomisation (R) on V3, and intervention V3-V7, with a follow-up two weeks later (V8). V6 was fully virtual, indicating that the participant did not visit the site. Prior to V3, V4, V5 and V7 the participant performed remote (coached) spirometry at home. During the study visits at the site, an additional spirometry was performed. Study Participant Feedback Questionnaire was collected at V3, V5, and V8. Patient experience interviews (i) were held after V3, V5, and V7. This image was taken and modified from the CRESCENDO protocol, published by Hughes and colleagues. 6 Topics in the Trial visit overview for the CRESCENDO trial. Screening occurred during V1-2 by the Health Care Professional (HCP). randomisation (R) on V3, and intervention V3-V7, with a follow-up two weeks later (V8). V6 was fully virtual, indicating that the participant did not visit the site. Prior to V3, V4, V5 and V7 the participant performed remote (coached) spirometry at home. During the study visits at the site, an additional spirometry was performed. Study Participant Feedback Questionnaire was collected at V3, V5, and V8. Patient experience interviews (i) were held after V3, V5, and V7. This image was taken and modified from the CRESCENDO protocol, published by Hughes and colleagues. 6 During the intervention period, participants completed V4-7. Remote coached spirometry was performed during V3-5 & V7. At V3 and V5, participants first underwent face-to-face spirometry on-site, followed by virtual spirometry via video link. At V4 and V7, virtual supervised, coached spirometry were performed away from site prior to attendance at the visit. V6 was fully virtual. This visit was performed through the UNIFY platform videoconference option. The trial was completed by a follow-up visit (V8). This study was added after commencement of the CRESCENDO trial and performed in a subset of the participating countries, namely: Bulgaria (BGR), Canada (CND), Poland (POL), Spain (ESP), United Kingdom (GBR), and the United States of America (USA). These countries were selected to include geographical and cultural diversity within the study sample. Participants were only interviewed once and interview timing was semi-randomized to take place after V3 (n=5), V5 (n=9) or V7 (n=7) to gather contextualized feedback. The study enrolled participants while the trial was ongoing, so those recruited after earlier visits (e.g. V3) were only eligible for interviews at later timepoints. The median number of days between visit and interview was 8 days (range: 0-20). From all participants who consented, we applied purposive sampling at the trial-site level, aiming to maximize the number of trial sites from which participants were included in the study. The study was approved by medical ethical committees in the participating countries. In Bulgaria, Canada, the United Kingdom and the United States, participants received an e-gift voucher their participation for a reasonable amount corresponding to their invested time, in the local currency. In Spain, participants received a financial compensation via bank-transfer. Polish participants could not be reimbursed due to local regulations. The study is reported in accordance with Consolidated Criteria for Reporting Qualitative Research (COREQ) criteria 20 (for COREQ checklist see Appendix I). Participants This study was implemented as part of the fourth version of the clinical study protocol of the CRESCENDO trial. All randomized participants of CRESCENDO in the participating countries were eligible for participation in this study. Trial participants were between 40 and 80 years of age, had moderate to severe COPD with risk of exacerbations, and no current or past diagnosis of asthma. A full list of inclusion and exclusion criteria can be found at https://clinicaltrials.gov. Participants were invited for participation in the study by the trial staff at their research site. Semi-Structured Interviews The study was set-up following grounded theory approach. Single ±60-minute semi-structured interviews were conducted remotely (telephone or videoconferencing; Zoom) using an interview guide. The topics incorporated in the interview guide can be found in Table 1 (full interview guide: Appendix II).Table 1.Topics in the Interview GuideTopics in the interview guideExperience of joining the trialDigital patient solutionsConsulting others about trial participation*Digital trial elements*Written information materials*​Motivation to participateStudy Participant Feedback Questionnaire (SPFQ)Communication during enrolmentNon-financial impactTrial siteFinancial impact(Virtual) visitsAppreciation/gratitudePreference for virtual or in-person visits*​Interactions with trial staffCommunication at the end of the trialCommunication during the trialPrevious trial experience(Virtual) spirometry​Experiences with the PEF spirometer*​*These items were added after revision of the interview guide. Table 1.Topics in the Interview GuideTopics in the interview guideExperience of joining the trialDigital patient solutionsConsulting others about trial participation*Digital trial elements*Written information materials*​Motivation to participateStudy Participant Feedback Questionnaire (SPFQ)Communication during enrolmentNon-financial impactTrial siteFinancial impact(Virtual) visitsAppreciation/gratitudePreference for virtual or in-person visits*​Interactions with trial staffCommunication at the end of the trialCommunication during the trialPrevious trial experience(Virtual) spirometry​Experiences with the PEF spirometer*​*These items were added after revision of the interview guide. Topics in the Interview Guide *These items were added after revision of the interview guide. Interviews were conducted in the participants native language by local moderators. Moderators from Bulgaria (male, Prof. MD), Spain (female, PhD MD) and Poland (male, Prof. MD) were clinical doctors and researchers. Moderators for Canada/United States (female, BCom) and United Kingdom (male, MSc) were qualitative researchers working as consultants. All received training on qualitative versus clinical interview techniques, the CRESCENDO trial, study objectives and the interview guide. Feedback on interview (technique) was provided using a standardized form and elucidated in a video-call with the study team. Feedback started after the first interview and was repeated after until all items were resolved. Moderators had no prior relationship with the participants. At the start of the interview moderators clarified their role and that participant responses would not be shared with site staff. Interviews were audio-recorded and transcribed verbatim. No field notes were taken during the interviews and transcripts were not returned to participants or moderators for commenting/correction. Interviews were translated to English and transcripts were anonymized before analysis. Study Participant Feedback Questionnaire (SPFQ) To gather participant feedback on their understanding of clinical trial procedures and experiences, the Study Participant Feedback Questionnaire (SPFQ) was used. The SPFQ was developed by TransCelerate BioPharma. 21 It was validated for diverse geographies and indications, 22 and is divided into three parts (Appendix V) which participants were asked to complete after different trial stages: Part A (within 1 month of enrolment), Part B (during trial), and Part C (post-trial). It assesses satisfaction with procedures, understanding of information, daily life impact, ability to ask questions, quality of responses, and post-trial support. The questionnaire contains 17 questions of which 12 (A1-A4, B1-B6, and C3-4) use a 5-point Likert scale (“strongly disagree” to “strongly agree”), four (B7, B8, C1 and C2) use a binary yes/no scale and one (C5) uses a reverse 5-point Likert scale (“much less than expected” to “much more than expected”). In this study, the SPFQ was implemented in December 2023 in six countries (BGR, CAN, ESP, GBR, POL, USA). SPFQ has recently been used as a measure of participant experience in an oncology study, where they assessed the SPFQ design and implementation in depth. 23 Data Analysis Data were analysed continuously using thematic analysis. The initial coding tree, based on the interview guide, was iteratively updated in response to the data, following a grounded theory approach which was selected for its suitability to the novelty of the study. Classic Glaserian grounded theory was implemented in our study, since the Glaserian approach emphasizes the attempt to discover unbiased knowledge about the world. 24 For the thematic analysis, coding was conducted by two researchers (R.K., PhD and W.v.d.V., MA) and clinical oversight of data analysis was provided by J.W.H.K. (Prof. MD.). The GPRI research institute participated in the CRESCENDO trial as a research site, giving R.K., W.v.d.V., Y.H.G. and J.W.H.K. in-depth insight into the study procedures, but GPRI did not recruit for this sub-study to prevent bias. The first seven interviews were independently double-coded by both researchers in the Dedoose (v9.2.6, SocioCultural Research Consultants, Los Angeles, CA). Reconciliation meetings to refine the coding tree took place after each interview. After the seventh interview, the calculated inter-rater reliability as a percentage of agreement of applied codes on pre-defined excerpts was sufficient (80.2%). Therefore, coding continued as single coding, where R.K. coded eight interviews and W.v.d.V. coded six interviews. Reconciliation meetings took place every five interviews to discuss additions to the coding tree (identified themes and codes in Figure 2). All interviews were recoded based on the updated coding tree.Figure 2.Coding tree. The coding tree presents an overview of the identified (sub-) themes in the study. Numbers in brackets present the number of interviews in which certain themes were discussed Coding tree. The coding tree presents an overview of the identified (sub-) themes in the study. Numbers in brackets present the number of interviews in which certain themes were discussed Saturation was defined as an absence of new codes or perspectives within a code for three consecutive interviews. Representative participant quotes were selected to best reflect the full participant sample and the various countries and identified by coded participant number and country. To analyse the participants’ views on the trial staff, descriptive terms in the sub-theme “interactions with trial staff” were extracted from all coded excerpts without limit per excerpt or participant. A word cloud was created using the wordcloud2 package in R. 25 Descriptive statistics on the participant population and the word cloud analysis were performed in R (v4.4.1, RStudio v2024.04.2, R Foundation for Statistical Computing, Vienna, Austria). Participants did not provide feedback on the findings that are shared in this article. Results Participant Characteristics Interviews Participant recruitment was performed by trial site staff and the number of participants who did not consent to participate in the study was not recorded. Table 2 provides a descriptive overview of participant characteristics.Table 2.Descriptive Characteristics of ParticipantsCharacteristicStudy population% Missing n 21​ Country n-participant[n-sites] ​ Bulgaria 2[2]​ Canada 3[1]​ Poland 4[2]​ Spain 4[2]​ United Kingdom 4[3]​ United States of America 4[2]​Age (mean (SD))66.8 (6.0)0.0Sex = Male (%)11 (52.4)0.0Number of exacerbations (past 12 months) (mean (SD))2.2 (1.7)19.0CAT score at start trial (mean (SD))14.1 (5.4)4.8Randomization order* (mean (min, max))3.0 (1, 6)0.0CAT: COPD assessment test.*This variable presents when sub-study participants (as the nth participant) were randomized into the trial at their trial site, and is indicative of how much experience the trial site had with the procedures in the clinical trial at the time of inclusion of sub-study participant. Table 2.Descriptive Characteristics of ParticipantsCharacteristicStudy population% Missing n 21​ Country n-participant[n-sites] ​ Bulgaria 2[2]​ Canada 3[1]​ Poland 4[2]​ Spain 4[2]​ United Kingdom 4[3]​ United States of America 4[2]​Age (mean (SD))66.8 (6.0)0.0Sex = Male (%)11 (52.4)0.0Number of exacerbations (past 12 months) (mean (SD))2.2 (1.7)19.0CAT score at start trial (mean (SD))14.1 (5.4)4.8Randomization order* (mean (min, max))3.0 (1, 6)0.0CAT: COPD assessment test.*This variable presents when sub-study participants (as the nth participant) were randomized into the trial at their trial site, and is indicative of how much experience the trial site had with the procedures in the clinical trial at the time of inclusion of sub-study participant. Descriptive Characteristics of Participants CAT: COPD assessment test. *This variable presents when sub-study participants (as the nth participant) were randomized into the trial at their trial site, and is indicative of how much experience the trial site had with the procedures in the clinical trial at the time of inclusion of sub-study participant. Saturation was reached for all identified main themes. Saturation was not reached for the sub-themes “how did you find out about the trial” and “consulting others”. Since our research has been a sub-study in a larger clinical trial, it was not possible to continue recruitment, as we were limited in the potential participants. Study Participation Feedback Questionnaire (SPFQ) 155 SPFQ questionnaires (54, 67, and 34 for parts A, B, and C, respectively) were distributed to 97 participants. Per the data cut-off in October 2024, 81 participants had completed 111 questionnaires (33, 51, and 27 for parts A, B, and C, respectively) resulting in an overall adherence of 71.6% (Appendix VI, Table S2). Most participants answered positively to most of the questions (>90% of positive answers for all questions apart from: C1-C3 with >80% of positive responses and C5, which is more balanced) indicating agreeable trial experience. The overall commitment required (question C5) has a more centered distribution around a neutral option (“More or less as expected”) with a slight bias to more negative (“more than expected”) responses (Figure 3).Figure 3.Overall SPFQ response distribution Overall SPFQ response distribution Thematic Analysis Based on the coding tree, we have organized the results in 8 subsections, namely “Overall experience”, “Joining the trial”, “Digital patient solutions”, “Virtual Trial elements”, “Trial activities and burden”, “Study staff”, “Communication during the trial”, and “Trial site facilities and financial compensation”. Overall Experience Participants in the CRESCENDO trial reported overall satisfaction with their trial participation:“I am generally satisfied. Very nice people, very kind and I really regret that it has already ended”. (P08, POL) “I am generally satisfied. Very nice people, very kind and I really regret that it has already ended”. (P08, POL) The most frequently mentioned motivation to continue the trial to the end was the desire to finish something participants had started:“Well because I jumped into something, me when I start something, well I'll see it to the end”. (P05, CND) “Well because I jumped into something, me when I start something, well I'll see it to the end”. (P05, CND) Additional motivations were the relationship with trial staff, receiving thorough medical checks, potential health benefits, and financial compensation. Some participants expressed that they recognized the importance of clinical trials for future patients:“I had a friend that passed away with COPD […] I would rather help people before they even get to that stage”. (P15, GBR) “I had a friend that passed away with COPD […] I would rather help people before they even get to that stage”. (P15, GBR) Eight of 21 participants had previously participated in clinical trials. Many participants expressed that previous experiences had been similar, although some mentioned that the CRESCENDO trial involved more time and tests:Res: “It was more time than my other studies I've been in.”Mod: “In what way was it more time? Was it the daily [activities] or the visits?” Res: “There was a lot more tests. It's a lot more tests”. (P21, USA) Res: “It was more time than my other studies I've been in.” Mod: “In what way was it more time? Was it the daily [activities] or the visits?” Res: “There was a lot more tests. It's a lot more tests”. (P21, USA) Some of the participants had points of improvement for the CRESCENDO trial, with many relating to the digital patient solutions:“Well, I think they have to make sure their software is working properly”. (P21, USA) “Well, I think they have to make sure their software is working properly”. (P21, USA) Joining the Trial Participants were invited via various routes: their healthcare provider (n=13), prior trial participation (n=4), open recruitment (n=3, i.e. through social media, radio advertisement and recruitment company) and through a professor (n=1, unclear role). Motivations to join the trial were split approximately evenly between individualistic and altruistic. Individualistic motivations were the hope the medication would improve their condition and receiving extensive and regular examinations:“I said, “Sure, why not? It sounds perfect.” Because I was deteriorating day by day”. (P12, ESP)“I would say that if I had been informed at the beginning that I wouldn't get such things, that you would just take some blood and that's it, I wouldn't have signed up for such a study at all, because I wouldn't get the main thing I went for, which is a thorough examination. Oh, and that was tomography, various kinds of blood tests, so that interested me”. (P08, POL) “I said, “Sure, why not? It sounds perfect.” Because I was deteriorating day by day”. (P12, ESP) “I would say that if I had been informed at the beginning that I wouldn't get such things, that you would just take some blood and that's it, I wouldn't have signed up for such a study at all, because I wouldn't get the main thing I went for, which is a thorough examination. Oh, and that was tomography, various kinds of blood tests, so that interested me”. (P08, POL) A few participants mentioned that they enjoyed feeling useful and doing something good. Altruistic motivations were wanting to help future patients and contributing to advancing the knowledge and science of COPD:“We're all individuals but I'm a person that needs to feel as though I'm useful. What better way than in a study helping hopefully to find some help for future generations with this disease?”. (P16, GBR)“So, I didn’t hesitate because participating allows you to collaborate with science”. (P11, ESP) “We're all individuals but I'm a person that needs to feel as though I'm useful. What better way than in a study helping hopefully to find some help for future generations with this disease?”. (P16, GBR) “So, I didn’t hesitate because participating allows you to collaborate with science”. (P11, ESP) A few participants also mentioned that the financial compensation motivated them to join, while others mentioned that they also would have joined without financial compensation. Several participants consulted other people, mainly family members and for one participant their general practitioner, while deciding whether to join. The majority of participants indicated that the initial communication about the trial was clear, and all their questions were answered. Written materials (Appendix III) were shared beforehand and considered clear and easy to understand:“It was well explained in the document. All the steps we have to do were all well explained. […] It was really well translated, very well, it was easy to understand. Oh yeah, they did a damn good job on that”. (P03, CND) “It was well explained in the document. All the steps we have to do were all well explained. […] It was really well translated, very well, it was easy to understand. Oh yeah, they did a damn good job on that”. (P03, CND) Some noted the volume of materials and admitted to not reading them, which they felt was unnecessary as they trust their healthcare provider/the trial staff:“I was signing those papers, but I didn’t read them”. (P09, POL)“People that are trained up, like my consultant, he knows. He doesn't sit and tell me that, but I just assume he's well-trained in it. Then that's faith enough for me. […] and I'm quite 100 percent sure they wouldn't ask me to do anything dangerous”. (P16, GBR) “I was signing those papers, but I didn’t read them”. (P09, POL) “People that are trained up, like my consultant, he knows. He doesn't sit and tell me that, but I just assume he's well-trained in it. Then that's faith enough for me. […] and I'm quite 100 percent sure they wouldn't ask me to do anything dangerous”. (P16, GBR) Digital Patient Solutions Participants were positive about the use of digital patient solutions and some expressed amazement about the fact that they could collect part of the data for this trial at home:Res: “They blow my mind with their, their innovation.”Mod: [laughs]Res: “But it's true, I would see that phone, I tell myself my, my god, we don't even need to go there”. (P04, CND) Res: “They blow my mind with their, their innovation.” Mod: [laughs] Res: “But it's true, I would see that phone, I tell myself my, my god, we don't even need to go there”. (P04, CND) Devices and application were considered easy to use despite a learning curve for some:“At the beginning, you know, it was a bit of a problem for me, to fill out that diary. And answering various questions because I'm not a fan of these touchscreen phones. But with the help of household members, my wife or daughter, they helped, and I mastered it, so there is no problem at all now”. (P07, POL) “At the beginning, you know, it was a bit of a problem for me, to fill out that diary. And answering various questions because I'm not a fan of these touchscreen phones. But with the help of household members, my wife or daughter, they helped, and I mastered it, so there is no problem at all now”. (P07, POL) When difficulties were experienced, the majority related to being unfamiliar with the iOS operating system:“I struggle with phones, and mine is a Samsung, not an Apple, making it more complicated”. (P13, ESP) “I struggle with phones, and mine is a Samsung, not an Apple, making it more complicated”. (P13, ESP) Most participants preferred using a provided phone for the trial procedures and keeping their own phones for personal use and to protect their privacy. In addition to daily data collection, it was found that participants used UNIFY for visit reminders and a reference for the trial information materials. While participants were generally positive about the digital patient solutions, most participants experienced various technical problems, which for some were bothersome:“I've had to go to the hospital multiple times because I lost the app. Other times, it was the spirometer not working or the spirometer app. It's been a hassle”. (P11, ESP)Res: “And then one time I was away at a wedding […] And the phone I guess had to be updated or something. Mm-hmm. And then it wouldn't let me back in. And I was very very sick when I went away to this wedding […] So I called the helpline […] And they were no help at all. And they were actually pretty obnoxious […]”Mod: “So that wasn't the site stuff. That was the Unify help line people?”Res: “Yeah. Yeah”.Mod: “Okay. Okay”.Res: “And I spoke to him and he was not helpful at all”. (P21, USA) “I've had to go to the hospital multiple times because I lost the app. Other times, it was the spirometer not working or the spirometer app. It's been a hassle”. (P11, ESP) Res: “And then one time I was away at a wedding […] And the phone I guess had to be updated or something. Mm-hmm. And then it wouldn't let me back in. And I was very very sick when I went away to this wedding […] So I called the helpline […] And they were no help at all. And they were actually pretty obnoxious […]” Mod: “So that wasn't the site stuff. That was the Unify help line people?” Res: “Yeah. Yeah”. Mod: “Okay. Okay”. Res: “And I spoke to him and he was not helpful at all”. (P21, USA) Support with technical problems was provided by trial site staff, whom one participant specifically mentioned to prefer over the UNIFY helpline:“Also, if you go in my menu, what's on there for the trial, it gives you help numbers to ring them for any problems with the equipment, but I always like to go through [Nurse 1] first. I find it easier than to ring the helpline. When the data wasn't going through, I could have rung the helpline but I didn't, I rang [Nurse 1]. […] Between us both, we got it”. (P16, GBR) “Also, if you go in my menu, what's on there for the trial, it gives you help numbers to ring them for any problems with the equipment, but I always like to go through [Nurse 1] first. I find it easier than to ring the helpline. When the data wasn't going through, I could have rung the helpline but I didn't, I rang [Nurse 1]. […] Between us both, we got it”. (P16, GBR) Staff told participants not to worry about the technical problems and reassured them that they were not at fault:“They calmed me down and told me not to worry, this happens, its communications, which sometime does not work”. (P01, BGR) “They calmed me down and told me not to worry, this happens, its communications, which sometime does not work”. (P01, BGR) Virtual Trial Elements Besides the digital patient solutions, the CRESCENDO trial included virtually coached spirometry and a fully virtual visit. As with the digital patient solutions, many participants experienced technical difficulties, and some visits had to be rescheduled as a consequence:“And they kept walking in and going. I said, no, you know, nothing for an hour and a half. We worked with them, and they could not get it. They were on the helpline. And so finally, she came in and said, all right, you go home. We have to reschedule”. (P21, USA) “And they kept walking in and going. I said, no, you know, nothing for an hour and a half. We worked with them, and they could not get it. They were on the helpline. And so finally, she came in and said, all right, you go home. We have to reschedule”. (P21, USA) Successful set-up of virtual connections was not dependent on the level of experience of the site in the trial (i.e.,having included other participants into CRESCENDO before, randomization order variable of Table 1). Virtually Coached Spirometry When video connections worked, many participants did not experience differences between in-person or virtually coached spirometry:“I don't think there was much difference at all. You know, it's done the same way, you know, and the coaching is they just tell you to keep blowing- keep blowing, keep blowing. But they could do that online too”. (P18, USA)“Well because I have in the end, it's like I have her next to me. […] She sees me too, so she knows that if I have a problem, she will tell me”. (P04, CND) “I don't think there was much difference at all. You know, it's done the same way, you know, and the coaching is they just tell you to keep blowing- keep blowing, keep blowing. But they could do that online too”. (P18, USA) “Well because I have in the end, it's like I have her next to me. […] She sees me too, so she knows that if I have a problem, she will tell me”. (P04, CND) And some recognized the benefits of remote data collection:“Yes, and I just think it's amazing how I can do something at home on this iPhone, and it can go to America. It can go anywhere where it needs to be gone”. (P16, GBR)“Because then you wouldn’t have to drive all the way there. You know, it takes much longer. We connect automatically. It’s a 10-minute thing”. (P21, USA) “Yes, and I just think it's amazing how I can do something at home on this iPhone, and it can go to America. It can go anywhere where it needs to be gone”. (P16, GBR) “Because then you wouldn’t have to drive all the way there. You know, it takes much longer. We connect automatically. It’s a 10-minute thing”. (P21, USA) Some participants preferred in-person spirometry measurements because they felt better supported and more motivated:Res: “I think the ones that you do at the hospital you're very much supported and guided.”Mod: “Just think, you know, considering you have a two-hour train journey to the hospital, would you prefer to be able to do more of them at home rather than.”Res: “No, no, no”. (P17, GBR)“Well, there is a lot of difference because in person, and even more so if you do it with the hospital equipment, well, you are much more attentive and pay more attention. […] with the two computer screens in front of you, displaying the amount of data and curves that come out. […] It involves you more because the situation is a bit imposing”. (P13, ESP) Res: “I think the ones that you do at the hospital you're very much supported and guided.” Mod: “Just think, you know, considering you have a two-hour train journey to the hospital, would you prefer to be able to do more of them at home rather than.” Res: “No, no, no”. (P17, GBR) “Well, there is a lot of difference because in person, and even more so if you do it with the hospital equipment, well, you are much more attentive and pay more attention. […] with the two computer screens in front of you, displaying the amount of data and curves that come out. […] It involves you more because the situation is a bit imposing”. (P13, ESP) Virtual Visit Despite positive experiences with virtual spirometry, most participants preferred in-person over virtual visits, primarily because they enjoyed the visits and interaction with site staff:“It makes you feel much better when you are face-to-face with the person, rather than on a video call”. (P01, BGR)Mod: “Would you have liked to have more visits be completed from home, like doing it that way or instead of going to the clinic or no?”Res: “No, I enjoyed going to the clinic and interacting with the nurses”. (P18, USA) “It makes you feel much better when you are face-to-face with the person, rather than on a video call”. (P01, BGR) Mod: “Would you have liked to have more visits be completed from home, like doing it that way or instead of going to the clinic or no?” Res: “No, I enjoyed going to the clinic and interacting with the nurses”. (P18, USA) Some felt virtual visits were appropriate for “check-ins”. Participants would feel comfortable doing remote “check-ins” since the other visits were so extensive:“I think because all my other phases have been so detailed and really making sure that my wellbeing is uppermost in their thoughts and everything to do this one [virtual study visit 6] at home, I feel quite confident”. (P17, GBR) “I think because all my other phases have been so detailed and really making sure that my wellbeing is uppermost in their thoughts and everything to do this one [virtual study visit 6] at home, I feel quite confident”. (P17, GBR) One participant saw a benefit in reduced travel burden:“Well, if it's just talking and no tests had to be taken, of course, it was wonderful. […] If I didn't have to get up and dressed and out. Because, for me, I have to feed the dogs and do all this stuff before I leave. So it was great”. (P21, USA) “Well, if it's just talking and no tests had to be taken, of course, it was wonderful. […] If I didn't have to get up and dressed and out. Because, for me, I have to feed the dogs and do all this stuff before I leave. So it was great”. (P21, USA) Trial Activities and Burden Participants did not consider the trial participation burdensome, particularly retirees:“It's not terribly a lot. Since I'm retired. It really doesn't matter”. (P19, USA) “It's not terribly a lot. Since I'm retired. It really doesn't matter”. (P19, USA) However, one participant noted giving up travel plans during the trial and another participant said their energy levels were reduced. Mostly, time investment and burden matched participants’ expectations. Although the burden was not considered high, many noted long visit durations and a high number of assessments:“And I can see that there are a lot of tests, even when they take the blood samples, there are many vials. They did a tomography, and an EKG of the heart, so they're really serious. I haven't had so many tests in a year as I've had in two weeks here”. (P06, POL)“Yes, when I went there, it lasted 4 hours, between 3 and 4 hours. And that's fine. How can I say… if we want things to improve, we need to give our time too”. (P03, CND) “And I can see that there are a lot of tests, even when they take the blood samples, there are many vials. They did a tomography, and an EKG of the heart, so they're really serious. I haven't had so many tests in a year as I've had in two weeks here”. (P06, POL) “Yes, when I went there, it lasted 4 hours, between 3 and 4 hours. And that's fine. How can I say… if we want things to improve, we need to give our time too”. (P03, CND) One participant had a visit split up into multiple visits because they were too tired to complete the visit in one day:“The first one went to the next and that was from nine o'clock till 12. Something wasn't going right, and I was getting tired. She sent me home to have a rest and then we went back to it. I can't remember what I had to go do when I went back at the same time. She likes you to have a little break. You're there like 10, five, six hours, and that's quite a long time doing them all and being probed”. (P15, GBR) “The first one went to the next and that was from nine o'clock till 12. Something wasn't going right, and I was getting tired. She sent me home to have a rest and then we went back to it. I can't remember what I had to go do when I went back at the same time. She likes you to have a little break. You're there like 10, five, six hours, and that's quite a long time doing them all and being probed”. (P15, GBR) Some participants found PEF performed at trial visits could be difficult and tiring. A few participants found the daily repetition overwhelming or annoying:“Sometimes I find it a bit overwhelming having to keep doing the thing every twice a day to give my details like the breathing”. (P15, GBR) “Sometimes I find it a bit overwhelming having to keep doing the thing every twice a day to give my details like the breathing”. (P15, GBR) However, daily trial activities were not bothersome and took little time (2-15 minutes):“Especially since there's a significant time span, around four hours, so you can always find a moment, right?”. (P06, POL) “Especially since there's a significant time span, around four hours, so you can always find a moment, right?”. (P06, POL) Participants from Spain, United States of America and Canada suggested that the time window to complete the eDiary was too short and ended too early, particularly in the evening:“Some of the evening diaries were a little inconvenient to schedule and remember if you had the activities”. (P18, USA) “Some of the evening diaries were a little inconvenient to schedule and remember if you had the activities”. (P18, USA) The only country with mixed attitudes toward time windows was GBR. Participants found devices easy to use and the eDiary and the PEF measurement easy to complete:“No, it's fairly straightforward. Yeah. So, you know that you've just got to blow into it three times. […] As long as it's shows that it's recorded, [uh] sometimes it tells you it fails for one reason or another, you just wait for it to come back, and you do it again”. (P17, GBR) “No, it's fairly straightforward. Yeah. So, you know that you've just got to blow into it three times. […] As long as it's shows that it's recorded, [uh] sometimes it tells you it fails for one reason or another, you just wait for it to come back, and you do it again”. (P17, GBR) Yet, other participants found the PEF measurement tiring, but less burdensome and tiring than spirometry:“Any spirometry is a little bit longer and more difficult than that one, which is just blowing three times”. (P11, ESP) “Any spirometry is a little bit longer and more difficult than that one, which is just blowing three times”. (P11, ESP) Study Staff Participants described their interactions with trial site staff as positive (Figure 4):“I am generally satisfied. Very nice people, very kind and I really regret that it has already ended”. (P08, POL)Figure 4.Word cloud of words used to describe the interactions with study site staff. Descriptive terms used in all coded quotes were listed to compile this word cloud. Word size is representative of word frequency “I am generally satisfied. Very nice people, very kind and I really regret that it has already ended”. (P08, POL) Word cloud of words used to describe the interactions with study site staff. Descriptive terms used in all coded quotes were listed to compile this word cloud. Word size is representative of word frequency Interactions with site staff impacted the overall satisfaction and experience in the trial:“That's why I said if I weren't happy with any of the team and they made me feel uncomfortable; I wouldn't be on the trial. They seemed to have picked such a great team, they're brilliant. I can't begin to tell you how they make me feel at home. I look forward to going and that's sad, isn't it? Fancy looking forward to going to the hospital?”. (P16, GBR) “That's why I said if I weren't happy with any of the team and they made me feel uncomfortable; I wouldn't be on the trial. They seemed to have picked such a great team, they're brilliant. I can't begin to tell you how they make me feel at home. I look forward to going and that's sad, isn't it? Fancy looking forward to going to the hospital?”. (P16, GBR) Only one participant (the first participant enrolled at the site) mentioned a negative experience with one staff member. Trial site staff was reported to be available, professional and competent, with a good understanding of the trial and the trial procedures. Additionally, all but one participant who discussed appreciation and gratitude reported perceiving these feelings through the way they were treated by the trial site staff:Mod: “Did you generally have the feeling that your contribution was valued?” Res: “Yes, yes, yes, yes, yes. Well yes, yes”Mod: “What… what made you feel that it was appreciated?”Res: “Well, it's well, you know. The enthusiasm with which they do it every time they see you, every time that they meet you and the importance it has for them too, they're, like I said earlier, I say it again, it's, they're passionate and they really take it to heart”. (P05, CND) Mod: “Did you generally have the feeling that your contribution was valued?” Res: “Yes, yes, yes, yes, yes. Well yes, yes” Mod: “What… what made you feel that it was appreciated?” Res: “Well, it's well, you know. The enthusiasm with which they do it every time they see you, every time that they meet you and the importance it has for them too, they're, like I said earlier, I say it again, it's, they're passionate and they really take it to heart”. (P05, CND) Communication During the Trial Participants were satisfied with the communication, reporting that trial procedures were clearly explained, and their questions were answered:“So, they always keep you informed on what's going on”. (P20, USA) “So, they always keep you informed on what's going on”. (P20, USA) There were a few instances of lacking information, mostly about the follow-up visit; either not knowing it would take place or expecting to continue medication until that visit (yet, this did not seem to be a big concern for participants):Res: “So I was a little surprised, though, that the Seven appointment where they said: Well, there's actually one more appointment. The follow-up.”Mod: “But if I understand correctly, that was a bit of a surprise that there would be one more. Okay.”Res: “Mm-hmm”. (P21, USA) Res: “So I was a little surprised, though, that the Seven appointment where they said: Well, there's actually one more appointment. The follow-up.” Mod: “But if I understand correctly, that was a bit of a surprise that there would be one more. Okay.” Res: “Mm-hmm”. (P21, USA) Examples of unclear information were identified both in early participants, and participants who joined later when the site had gained more experience. One participant articulated that they would have liked to receive more detailed information, for example about the parameters that were assessed in the various blood tests. This aligns with SPFQ results where respondents were overwhelmingly comfortable asking questions and satisfied with received answers (questions A4, B5-6), except for a notable increase in negative answers to questions about end-of-trial communication, including access to results and future support (questions C1-3). Trial Site Facilities and Financial Compensation Participants reported general satisfaction with trial site facilities and financial compensation. The waiting and assessment rooms were considered appropriate with sufficient privacy. Waiting times were short and trial sites were easily accessible:“As for the interiors of the clinic in general, there is a place to sit both comfortably, calm, quiet, warm. So, you can wait for one examination after the next with pleasure”. (P10, POL) “As for the interiors of the clinic in general, there is a place to sit both comfortably, calm, quiet, warm. So, you can wait for one examination after the next with pleasure”. (P10, POL) Financial compensation and reimbursement were well-organized and received promptly:Res: “I didn't have to pay for any cost”.Mod: “[hmm] Okay”.Res: “That, that cost me nothing to participate in the study…”Mod: “[hmm]”Res: “They reimbursed me for everything. So no, it cost me nothing”.Mod: “And what did you think of the speed and the amount of the reimbursement of study-related costs?”Res: “Well the speed was fine. She gave me my check when I entered, I wasn't even [uh] we hadn't even sat down yet and I already had my check”. (P03, CND) Res: “I didn't have to pay for any cost”. Mod: “[hmm] Okay”. Res: “That, that cost me nothing to participate in the study…” Mod: “[hmm]” Res: “They reimbursed me for everything. So no, it cost me nothing”. Mod: “And what did you think of the speed and the amount of the reimbursement of study-related costs?” Res: “Well the speed was fine. She gave me my check when I entered, I wasn't even [uh] we hadn't even sat down yet and I already had my check”. (P03, CND) Participants were asked about their experience with the SPFQ and the cough study (two optional sub-studies of the CRESCENDO trial), but these findings are not reported here due to the limited data. Discussion Incorporating patients as a partner in their care enhances study design, promoting more relevant and innovative outcomes. 3 This study explored experiences of participants enrolled into a multi-country phase IIa clinical trial in COPD, CRESCENDO, focusing on the feasibility and acceptability of digital patient solutions and virtual trial procedures, including virtually coached spirometry. The CRESCENDO study was innovative with its digital solutions and included patients as part of the Clinical Project Team to develop the study. For these two reasons, the CRESCENDO study was selected for the current patient experience sub-study. Overall, participants were very satisfied with their trial participation in CRESCENDO. The acceptability and feasibility of the digital patient solutions used for the daily collection of data at home were generally high as they were considered easy to use, though technical issues caused frustration. Although the SPFQ contained no questions specific to digital solutions, >95% of SPFQ respondents found the time required for data collection (questions B7) and the impact of the trial on daily activities (questions B8) acceptable. Many participants reported difficulties with setting up the video-connections required for remote spirometry and virtual visits. When functioning, virtually coached spirometry was well received. This mirrors findings from a cystic fibrosis study, where the method was well accepted but hampered by technical issues with video camera and device connectivity. 26 Minimizing technical issues is therefore critical for implementation of digital patient solutions and virtual trial elements. Previous research 27 has offered recommendations for this. For instance, to have video connections that run as smoothly as possible, environmental distractions must be avoided (e.g., by silencing phone notifications and/or having the appointment in a quiet room). Regarding device connectivity, by combining thorough Quality Assurance (QA) (i.e.,process of systematically testing an app for defects) with User Acceptance Testing (UAT) (i.e.,real users verifying that the app works correctly in real-world scenarios), the likelihood of technical glitches appearing during the clinical trial can be significantly reduced. Also, connectivity issues must be troubleshot 5-10 minutes before the start of the time scheduled for the visit and, if they still occurred, the video can be turned off and/or the participants can be offered a phone call instead. 27 Most participants preferred in-person visits, mainly because they enjoyed the interactions with trial staff and for many this was valued more than reduced travel burden. The SPFQ showed >95% responders found their trial visits well-organized (question B2) and scheduled conveniently (questions B3) supporting diminished differences between in-person and virtual visits. This supports our finding that personal interactions remain important and appreciated during a clinical trial. However, making sure that patients have autonomy to choose between in-person and online visits is paramount. There is a nuanced balance between preferring in-person visits and accepting virtual visits under certain conditions. For example, a 2023 survey of over 12,000 participants found that 58% considered “having some study visits be virtual” a reason to stay enrolled in a study. 28 Conversely, a large survey study in the USA found lower acceptance of virtual clinical care visits when patients had a prior relationship with the clinician, regardless of age. 29 Importantly, not all participants experienced virtual trial elements at the time they were interviewed, as these occurred later in the trial. Therefore, the virtual trial elements were only discussed with a subset of the participants. Further studies exploring participants’ experience of virtual visits specifically in clinical trials would help inform future trials. Participant perspectives concerning virtually coached spirometry, the virtual visit and the preference for provided versus bring your own device (BYOD) varied. Participant characteristics (e.g., digital literacy, geography, employment status) may affect the personal preferences. The mean age in this study was 67 years, and earlier studies comparing provided devices and BYOD found a similar split in preference in a COPD population (mean age 59), 30 while a younger population with chronic health conditions (mean age 49) preferred BYOD. 31 Offering options to suit participant preferences can enhance acceptability of trial elements and thereby enhance participant recruitment, compliance and retention. Future studies into participant experiences may elucidate general preferences in different (patient) populations. This study highlighted the central role that trial staff play in shaping participants’ experiences. Participants were almost exclusively positive about the trial staff, both in the interviews and the SPFQ (questions A4, B4-6). Staff influenced motivation, satisfaction with communication preference for in-person visits and perceived appreciation for participation. Additionally, when experiencing technical issues, the hindrance to acceptability of the digital patient solutions, participants turned to the site staff for assistance instead of the available helpdesk. Supporting trial staff in their central role will enhance participants’ trial experience. The multinational scope of this study provided some insights into cultural differences, though this was not an objective of the current study and the sample size does not allow for strong conclusions. Two themes were identified. First, time-windows (especially PM) for daily data collection were considered too narrow in Spain and North America, but not in Eastern Europe. Differences may reflect cultural rhythms of activities outside the home suggesting a benefit of regionally adapted time-windows. Second, most participants from the USA indicated that financial compensation motivated them to join the trial, similar to previous findings in the USA,32,33 while all participants who said they would have participated without compensation were from the UK. There is little research assessing cultural differences in participants’ clinical trial experience, but for example another study found that as compared to ‘white’ participants, British South-Asian participants preferred female trial staff among other differences. 34 Accommodating such cultural differences may contribute to optimising diverse and inclusive participation in clinical trials. 35 Interviews were consistent with SPFQ responses, strengthening the validity of the interview results and the utility of the SPFQ to measure patient experience. Due to late introduction of the SPFQ in only a subset of countries, we lack a full global picture, early-stage data and Part A response rates. The lower Part C response rate may be explained by the change to the schedule of activities once the target number of events was reached for the study. Participants might have been reluctant to complete another SPFQ feedback so quickly. A lower completion rate potentially bias the results and so in the future it may be important to implement the SPFQ as a mandatory feedback mechanism. 23 When interpreting the results of this study, it is important to keep selection and recall bias in mind. Although participation in the study was offered to all participants of included countries, more motivated participants may have been more likely to join this sub-study. Those who withdrew from CRESCENDO were not included, potentially excluding more negative perspectives. Nevertheless, the study presents a heterogenous population with a range of perspectives on the trial experience. To minimize recall bias, participants were interviewed at various time-points. No differences were found in participant responses between time-points, though some participants struggled to recall trial elements and procedures. The interview guide was updated twice to improve clarity, which did improve recognition, but recall limitations likely remained. Furthermore, the study design did not allow linking SPFQ responses and interviews at the individual level, preventing direct comparison. Still, findings from both methods were consistent, highlighting their complimentary value. Interviews can help clarify trends captured with the SPFQ and support targeted trial improvements. Regarding the thematic analysis, we acknowledge that saturation was not achieved for certain themes (due to the limitation in continuing participants recruitment). However, we do expect that the most relevant topics in the themes were uncovered. In conclusion, this study offers insight into experiences of patients with COPD as participants in an international clinical trial. It highlights the promise of digital and virtual trial elements, opportunities for improvement (e.g., minimizing technical issues and maximizing flexibility), and the importance of study site staff. Practical recommendations for designing a clinical trial, as identified in this study, include ensuring site staff is well-trained in use of digital tools and support, testing digital solutions in advance, allowing choice between virtual or in-person elements, and offering preferred devices/operating systems (see Box 1). Future research in other (respiratory) populations (e.g., asthma), would expand our understanding of the acceptability and feasibility of digital and virtual elements in clinical trials.Box 1. Practical recommendations when designing a clinical trial to maximize patient experience and success of digital solutions • Inform trial site staff about their central role in making trial participation an enjoyable experience for participants. By highlighting the importance of sites, they can deliver the study optimally for participants.• Enable the site staff to understand and use the digital solutions and they can help the patients better.• Perform pre-launch usability testing of digital patient solutions specific to your trial with both potential participants and trial staff to minimize technical errors and glitches. Aim to have a System Usability Score above 68 points (which is the average score) 36 • Provide site staff with at least one training set (device(s), phone application, etc.) that they could use to get familiar with the study procedures and practice before they screen and randomize their first patient• Incorporate the right digital solutions for the right patient by involving patients in decision-making• Allow participants to choose whether to perform trial elements virtually or in-person• When providing a phone, give participants the option to choose their preferred operating system (especially in an elderly population), or bringing their own device• When incorporating digital patient solutions, make sure technical issues are minimised and site and participants are well supported• When setting time windows for daily measurements, conduct patient research to understand cultural differences. Consider extending an evening window until after midnight (12:00 PM). Box 1. Practical recommendations when designing a clinical trial to maximize patient experience and success of digital solutions • Inform trial site staff about their central role in making trial participation an enjoyable experience for participants. By highlighting the importance of sites, they can deliver the study optimally for participants.• Enable the site staff to understand and use the digital solutions and they can help the patients better.• Perform pre-launch usability testing of digital patient solutions specific to your trial with both potential participants and trial staff to minimize technical errors and glitches. Aim to have a System Usability Score above 68 points (which is the average score) 36 • Provide site staff with at least one training set (device(s), phone application, etc.) that they could use to get familiar with the study procedures and practice before they screen and randomize their first patient• Incorporate the right digital solutions for the right patient by involving patients in decision-making• Allow participants to choose whether to perform trial elements virtually or in-person• When providing a phone, give participants the option to choose their preferred operating system (especially in an elderly population), or bringing their own device• When incorporating digital patient solutions, make sure technical issues are minimised and site and participants are well supported• When setting time windows for daily measurements, conduct patient research to understand cultural differences. Consider extending an evening window until after midnight (12:00 PM). • Inform trial site staff about their central role in making trial participation an enjoyable experience for participants. By highlighting the importance of sites, they can deliver the study optimally for participants. • Inform trial site staff about their central role in making trial participation an enjoyable experience for participants. By highlighting the importance of sites, they can deliver the study optimally for participants. • Enable the site staff to understand and use the digital solutions and they can help the patients better.• Perform pre-launch usability testing of digital patient solutions specific to your trial with both potential participants and trial staff to minimize technical errors and glitches. Aim to have a System Usability Score above 68 points (which is the average score) 36 • Provide site staff with at least one training set (device(s), phone application, etc.) that they could use to get familiar with the study procedures and practice before they screen and randomize their first patient • Enable the site staff to understand and use the digital solutions and they can help the patients better.• Perform pre-launch usability testing of digital patient solutions specific to your trial with both potential participants and trial staff to minimize technical errors and glitches. Aim to have a System Usability Score above 68 points (which is the average score) 36 • Provide site staff with at least one training set (device(s), phone application, etc.) that they could use to get familiar with the study procedures and practice before they screen and randomize their first patient • Perform pre-launch usability testing of digital patient solutions specific to your trial with both potential participants and trial staff to minimize technical errors and glitches. Aim to have a System Usability Score above 68 points (which is the average score) 36 • Perform pre-launch usability testing of digital patient solutions specific to your trial with both potential participants and trial staff to minimize technical errors and glitches. Aim to have a System Usability Score above 68 points (which is the average score) 36 • Provide site staff with at least one training set (device(s), phone application, etc.) that they could use to get familiar with the study procedures and practice before they screen and randomize their first patient • Provide site staff with at least one training set (device(s), phone application, etc.) that they could use to get familiar with the study procedures and practice before they screen and randomize their first patient • Incorporate the right digital solutions for the right patient by involving patients in decision-making• Allow participants to choose whether to perform trial elements virtually or in-person• When providing a phone, give participants the option to choose their preferred operating system (especially in an elderly population), or bringing their own device • Incorporate the right digital solutions for the right patient by involving patients in decision-making• Allow participants to choose whether to perform trial elements virtually or in-person• When providing a phone, give participants the option to choose their preferred operating system (especially in an elderly population), or bringing their own device • Allow participants to choose whether to perform trial elements virtually or in-person • Allow participants to choose whether to perform trial elements virtually or in-person • When providing a phone, give participants the option to choose their preferred operating system (especially in an elderly population), or bringing their own device • When providing a phone, give participants the option to choose their preferred operating system (especially in an elderly population), or bringing their own device • When incorporating digital patient solutions, make sure technical issues are minimised and site and participants are well supported • When incorporating digital patient solutions, make sure technical issues are minimised and site and participants are well supported • When setting time windows for daily measurements, conduct patient research to understand cultural differences. Consider extending an evening window until after midnight (12:00 PM). • When setting time windows for daily measurements, conduct patient research to understand cultural differences. Consider extending an evening window until after midnight (12:00 PM). Supplemental Material Supplemental Material - Participant Acceptability and Feasibility of Virtual and Digital Health Solutions in a Phase IIa COPD Trial Supplemental Material for Participant Acceptability and Feasibility of Virtual and Digital Health Solutions in a Phase IIa COPD Trial by R. Kat, W. van der Veen, Y. H. Gerritsma, M. T. Leving , W. Dott, O. Elizarova, R. Hughes, C. Jonstrand, C. Kristensson, Andrzej Nowojewski, Alex Wheal, J. W. H. Kocks in Journal of Patient Experience